Caligan Partners’ Dave Johnson on MorphoSys’ $MOR change from royalty play to traditional biotech

Dave Johnson, Managing Partner at Caligan Partners, makes his second appearance to discuss his thesis on MorphoSys AG (FSE: MOR; NASDAQ: MOR), including: history of the company, change in business strategy from a royalty play to traditional biotech, Pelabresib clinical trials for Myelofibrosis indication and more!

For more information about Dave Johnson and Caligan Partners, please visit: https://www.caliganpartners.com/

Chapters:

[0:00] Introduction + Episode sponsor: Stream by Alphasense

[1:47] What is MorphoSys $MOR and why is it so interesting?

[9:58] How and why Caligan Partners got involved in $MOR

[19:34] What is Pelabresib and why Dave/Caligan are excited about this with regard to $MOR

[27:27] Clinical trial enrollment for Pelabresib / Constellation Pharmaceuticals acquisition

[33:09] Next steps for Pelabresib

[36:04] Dave's thoughts on the timing of Pelabresib being approved (if approved)

[38:25] Pressure on biotech management teams from boards to get deals done

[40:56] Probability of success of Pelabresib and how do you value $MOR as a result

[47:16] Constellation Pharmaceuticals acquisition process

[50:25] Buying back convertible bonds and why that was an accretive transaction

[52:55] Final thoughts on $MOR

Today's episode is sponsored by: Stream by Alphasense

Are traditional expert calls in the investment world becoming obsolete? According to Stream, they are, and you can access primary research easily and efficiently through their platform. With Stream, you'll have the right insights at your fingertips to make the best investment decisions. They offer a vast library of over 26,000 expert transcripts, powered by AI search technology. Plus, they provide competitive rates on expert call services, and you can even have an experienced buy-side analyst conduct the calls for you.

But that's not all. Stream also provides the ability to engage with experts 1-on-1 and get your calls transcribed free-of-charge—all for 40% less than you would pay for 20 calls in a traditional expert network model. So, if you're looking to optimize your research process and increase ROI on investment research spend, Stream has the solution for you. Head over to their website at streamrg.com to learn more. Thanks for listening, and we'll catch you next time. For more information: https://www.streamrg.com/